MT-2

Melanotan II (MT-2) is a synthetic cyclic heptapeptide that mimics the action of α-MSH, a hormone involved in various physiological processes including skin pigmentation, sexual arousal, and appetite regulation. It acts as a non-selective agonist of the melanocortin receptors (MC1, MC3, MC4, and MC5), with a particular emphasis on MC1R for pigmentation and MC3R/MC4R for sexual function and metabolic effects. Originally developed as a potential photoprotective agent to induce tanning without UV exposure, its broader effects on sexual function and appetite suppression were subsequently observed during research. Its ability to stimulate melanin production makes it a subject of interest in dermatology research, while its impact on central nervous system pathways related to sexual arousal and energy homeostasis positions it in metabolic and neurological studies. This product is for research purposes only and not for human consumption.

Research into Melanotan II has primarily focused on its interaction with the melanocortin system. Studies have shown that MT-2 stimulates melanogenesis by activating the MC1 receptor on melanocytes, leading to increased production of melanin and subsequent skin darkening. This mechanism is being explored for its potential in preventing UV-induced skin damage. Beyond pigmentation, MT-2's agonism of MC3 and MC4 receptors has been linked to its effects on sexual function and appetite. Preclinical and early clinical research has indicated that MT-2 can induce erections in males and enhance sexual arousal in both males and females, suggesting a role for the central melanocortin system in sexual behavior. Furthermore, activation of MC4R has been implicated in appetite suppression and increased lipolysis, leading to investigations into MT-2's potential as an anti-obesity agent. These findings underscore the pleiotropic effects of melanocortin receptor activation. This product is for research purposes only and not for human consumption.

Research protocols have explored a range of dosages, typically administered via subcutaneous injection. Common research dosages often fall within 0.25mg to 1mg per administration, usually once daily or every other day, depending on the specific research objective and observed effects. Researchers should carefully titrate dosages and monitor for any adverse reactions in experimental models. All dosing information is for research reference only.